What is CAR T-cell Therapy for Myeloma?
What Surface Protein Do CAR T-cell Therapies Target on Myeloma?
What’s the Difference Between CAR T-cell Therapy and an Autologous Stem Cell Transplant?
When to Consider CAR T-cell Therapy?
Who is Eligible for CAR-T?
CAR‑T Clinical Trials Test Treatment as an Earlier Option
What to Consider Before CAR T-cell Therapy
Benefits and Barriers to CAR‑T
FDA-Approved Myeloma CAR T-cell Therapies
How Effective is Cilta-cel (Carvykti)?
How Effective is Ide-cel (Abecma)?
Side Effect Management of CAR T-cell Therapy for Multiple Myeloma
Cytokine Release Syndrome (CRS)
Muscle, Joint, and Bone Pain
A Look Ahead: The Future of Myeloma CAR T-cell Therapy
Caregiver Role in Myeloma CAR-T
How to Support A Person with Myeloma Receiving CAR T-cell Therapy
Supportive Measures for Caregivers
What If I Don’t Have a Caregiver for CAR T-Cell Therapy?
Communicating with Your Healthcare Team
When to Ask About CAR T-cell Therapy
Involving Care Partners in the Conversation
When to Get a Second Opinion?
Keep Track of What You Learn
Keeping Your Care Team Informed
Transferring Your Care to Your Clinic
Coming Home and Follow-up Appointments
Ongoing Monitoring, Medications, and Life After Treatment
Financial Resources for Myeloma CAR-T
Understanding Medicare Coverage for Myeloma CAR-T
Pharmaceutical Company CAR-T Assistance Programs
Explore Additional Financial Resources
![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}